Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer's disease

• Published in: Journal of neuroinflammation 2021-11, Vol.18 (1), p.273-273, Article 273
• Main Authors: Banik, Avijit, Amaradhi, Radhika, Lee, Daniel, Sau, Michael, Wang, Wenyi, Dingledine, Raymond, Ganesh, Thota
• Format: Article
• Language: English
• Subjects: Age; Alzheimer Disease - drug therapy; Alzheimer Disease - pathology; Alzheimer's disease; Amyloid; Anemia - blood; Animals; Antagonists (Biochemistry); Biological response modifiers; Blood Cell Count; Body weight; Brain; CD11b antigen; Cell receptors; Cognitive ability; Cyclooxygenase 2 - genetics; Cyclooxygenase-2; Development and progression; Drinking water; Drug therapy; EP2; Female; Glial fibrillary acidic protein; Health aspects; Humans; IL-1β; Inflammation; Inflammation Mediators - metabolism; Interleukin 6; Lipopolysaccharide; Lipopolysaccharides; Lipopolysaccharides - pharmacology; Male; Mice; Mice, Transgenic; Microgliosis; Monocyte chemoattractant protein 1; mRNA; Neocortex; Neurodegeneration; Neurodegenerative diseases; Neurofibrillary tangles; Neuroglia - metabolism; Neuroinflammation; Neuroinflammatory Diseases - drug therapy; Neuroinflammatory Diseases - pathology; Pathology; Pharmacology, Experimental; Plaque, Amyloid - metabolism; Plaque, Amyloid - pathology; Prostaglandins E; Receptors, Prostaglandin E, EP2 Subtype - antagonists & inhibitors; Sex Characteristics; Signal transduction; Signal Transduction - drug effects; TG11-77.HCl; Transgenic mice; Tumor necrosis factor; Two-hit 5xFAD
• ISSN: 1742-2094; 1742-2094
• DOI: 10.1186/s12974-021-02297-7

Alzheimer's disease (AD) causes substantial medical and societal burden with no therapies ameliorating cognitive deficits. Centralized pathologies involving amyloids, neurofibrillary tangles, and neuroinflammatory pathways are being investigated to identify disease-modifying targets for AD. Cyclooxygenase-2 (COX-2) is one of the potential neuroinflammatory agents involved in AD progression. However, chronic use of COX-2 inhibitors in patients produced adverse cardiovascular effects. We asked whether inhibition of EP2 receptors, downstream of the COX-2 signaling pathway, can ameliorate neuroinflammation in AD brains in presence or absence of a secondary inflammatory stimuli. We treated 5xFAD mice and their non-transgenic (nTg) littermates in presence or absence of lipopolysaccharide (LPS) with an EP2 antagonist (TG11-77.HCl). In cohort 1, nTg (no-hit) or 5xFAD (single-hit-genetic) mice were treated with vehicle or TG11-77.HCl for 12 weeks. In cohort 2, nTg (single-hit-environmental) and 5xFAD mice (two-hit) were administered LPS (0.5 mg/kg/week) and treated with vehicle or TG11-77.HCl for 8 weeks. Complete blood count analysis showed that LPS induced anemia of inflammation in both groups in cohort 2. There was no adverse effect of LPS or EP2 antagonist on body weight throughout the treatment. In the neocortex isolated from the two-hit cohort of females, but not males, the elevated mRNA levels of proinflammatory mediators (IL-1β, TNF, IL-6, CCL2, EP2), glial markers (IBA1, GFAP, CD11b, S110B), and glial proteins were significantly reduced by EP2 antagonist treatment. Intriguingly, the EP2 antagonist had no effect on either of the single-hit cohorts. There was a modest increase in amyloid-plaque deposition upon EP2 antagonist treatment in the two-hit female brains, but not in the single-hit genetic female cohort. These results reveal a potential neuroinflammatory role for EP2 in the two-hit 5xFAD mouse model. A selective EP2 antagonist reduces inflammation only in female AD mice subjected to a second inflammatory insult.